drugset / Trial / NCT05091086
The Optimal Long Term Treatment Strategy of Anti-resorptive Medications
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is to investigate whether the alternating use of Prolia (Denosumab) and Aclasta (Zoledronic acid) can continue to increase bone density.
Timeline
- Start
- 2021-11-20
- Primary completion
- 2025-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | — | — |
| Subject | Zoledronic acid | Other / unclassified | — | — |